Igor Wolfgang Blau

Long-Term Control of HIV by <i>CCR5</i> Delta32/Delta32 Stem-Cell Transplantation

Gero Hütter, Daniel Nowak, Maximilian Mossner et al. · New England Journal of Medicine · 2009 · 1.8K citations · Full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Journal of Clinical Oncology · 2012 · 819 citations · Full text

Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells

Quirin Hammer, Timo Rückert, Eva Maria Borst et al. · Nature Immunology · 2018 · 401 citations

Natural Killer Cells, Peptide-specific Recognition, Adaptive Immune System +10

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Kai Neben, Henk M. Lokhorst, Anna Jauch et al. · Blood · 2011 · 353 citations